Effects of Rituximab on Atherosclerotic Biomarkers in Kidney Transplant Recipients

Creative Commons License

Alıyeva N., Demır E., Akgul S. , Temurhan S. , Ucar A., Dırım A. B. , ...Daha Fazla

TRANSPLANTATION PROCEEDINGS, cilt.51, sa.4, ss.1118-1120, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 51 Konu: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.transproceed.2019.01.106
  • Sayfa Sayıları: ss.1118-1120


Introduction. Cardiovascular disease is the leading cause of mortality in kidney transplant recipients. Rituximab is widely used in kidney transplantation for a variety of situations, and rituximab may inhibit some cytokines and antibodies that may play an active role in the atherosclerotic process. The aim of the study was to evaluate the efficacy of rituximab on atherosclerosis biomarkers in kidney transplant recipients.